|
BR122020020745B8
(pt)
|
2010-07-22 |
2023-10-31 |
Gilead Sciences Inc |
Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
|
|
RU2016146365A
(ru)
*
|
2014-05-13 |
2018-06-19 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
|
|
TWI767201B
(zh)
|
2014-10-29 |
2022-06-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
CN107207505B
(zh)
*
|
2015-02-11 |
2018-12-14 |
豪夫迈·罗氏有限公司 |
治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
|
WO2016177655A1
(en)
|
2015-05-04 |
2016-11-10 |
F. Hoffmann-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
JP6506880B2
(ja)
|
2015-07-27 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
|
|
JP6559324B2
(ja)
|
2015-07-28 |
2019-08-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
|
|
SI3349758T1
(sl)
|
2015-09-16 |
2022-08-31 |
Gilead Sciences, Inc. |
Postopki za zdravljenje okužb z virusom arenaviridae
|
|
US20200270265A1
(en)
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
JP6904970B2
(ja)
|
2016-03-07 |
2021-07-21 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
CN109414508A
(zh)
|
2016-05-27 |
2019-03-01 |
吉利德科学公司 |
使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
CN109843296A
(zh)
|
2016-06-10 |
2019-06-04 |
英安塔制药有限公司 |
乙型肝炎抗病毒药剂
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
CN109414448B
(zh)
*
|
2016-06-17 |
2021-10-26 |
豪夫迈·罗氏有限公司 |
用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
|
|
CN109415368B
(zh)
*
|
2016-07-14 |
2021-04-30 |
豪夫迈·罗氏有限公司 |
用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
CN110156774A
(zh)
|
2016-07-29 |
2019-08-23 |
新波制药有限公司 |
用于治疗hbv感染的新颖治疗剂
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
CN109923106B
(zh)
|
2016-09-02 |
2022-09-13 |
吉利德科学公司 |
toll样受体调节剂化合物
|
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
IL265921B2
(en)
|
2016-10-14 |
2024-05-01 |
Prec Biosciences Inc |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
US11124495B2
(en)
|
2016-11-03 |
2021-09-21 |
Hoffmann-La Roche, Inc. |
Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection
|
|
CN110088103B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶化合物
|
|
CN110088104B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物
|
|
TWI794190B
(zh)
*
|
2016-11-07 |
2023-03-01 |
加拿大商愛彼特生物製藥公司 |
含有取代的吡啶酮之三環化合物及其使用方法
|
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
|
CN106810548B
(zh)
*
|
2017-01-13 |
2019-02-15 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
UY37581A
(es)
|
2017-02-02 |
2018-08-31 |
Gilead Sciences Inc |
Compuestos para el tratamiento de la infección por virus de la hepatitis b
|
|
DK3587420T3
(da)
*
|
2017-02-23 |
2021-06-07 |
Fujian Cosunter Pharmaceutical Co Ltd |
Tricyklisk forbindelse og anvendelser heraf
|
|
US10682368B2
(en)
|
2017-03-14 |
2020-06-16 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
|
AU2018238138A1
(en)
|
2017-03-21 |
2019-10-17 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
AR111419A1
(es)
*
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
AU2018262501B2
(en)
|
2017-05-01 |
2020-12-10 |
Gilead Sciences, Inc. |
Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
WO2019014247A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
US10952978B2
(en)
|
2017-08-28 |
2021-03-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
SI3692040T1
(sl)
*
|
2017-10-05 |
2023-05-31 |
Glaxosmithkline Intellectual Property Development Limited |
Kemijske spojine
|
|
UA126931C2
(uk)
|
2017-10-16 |
2023-02-22 |
Ф. Хоффманн-Ля Рош Аг |
МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
|
|
US12171755B2
(en)
|
2017-10-25 |
2024-12-24 |
Children's Medical Center Corporation |
PAPD5 inhibitors and methods of use thereof
|
|
EP3710455A1
(en)
|
2017-11-17 |
2020-09-23 |
Novartis AG |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
TW201927789A
(zh)
|
2017-12-06 |
2019-07-16 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
|
TW201936192A
(zh)
|
2017-12-06 |
2019-09-16 |
美商因那塔製藥公司 |
B 型肝炎抗病毒試劑
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
JP2021507906A
(ja)
*
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
|
TW201930276A
(zh)
*
|
2017-12-22 |
2019-08-01 |
德商拜耳廠股份有限公司 |
羥基異㗁唑啉及其衍生物
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
TWI707849B
(zh)
|
2018-02-13 |
2020-10-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
|
CN111801331A
(zh)
|
2018-02-28 |
2020-10-20 |
诺华股份有限公司 |
吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
|
|
US11702427B2
(en)
|
2018-03-12 |
2023-07-18 |
Arbutus Biopharma Corporation |
Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
AU2019252441A1
(en)
|
2018-04-12 |
2020-10-22 |
Arbutus Biopharma Corporation |
Methods for preparing substituted pyridinone-containing tricyclic compounds
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
SG11202012759XA
(en)
|
2018-07-03 |
2021-01-28 |
Hoffmann La Roche |
Oligonucleotides for modulating tau expression
|
|
EP3820572B1
(en)
|
2018-07-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CN110862390B
(zh)
|
2018-08-28 |
2023-05-09 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
UY38383A
(es)
|
2018-09-21 |
2020-04-30 |
Enanta Pharm Inc |
Heterociclos funcionalizados como agentes antivirales
|
|
CA3111046A1
(en)
|
2018-09-30 |
2020-04-02 |
Sunshine Lake Pharma Co., Ltd. |
Fused tetracyclic compounds and uses thereof in medicine
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
TW202136261A
(zh)
|
2018-10-31 |
2021-10-01 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
TWI721623B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
US11198693B2
(en)
|
2018-11-21 |
2021-12-14 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN114014854B
(zh)
*
|
2019-01-08 |
2023-04-07 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
KR102707808B1
(ko)
|
2019-03-07 |
2024-09-19 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
US12486234B2
(en)
|
2019-04-24 |
2025-12-02 |
Children's Medical Center Corporation |
PAPD5 inhibitors and methods of use thereof
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
CN119770638A
(zh)
|
2019-09-30 |
2025-04-08 |
吉利德科学公司 |
Hbv疫苗和治疗hbv的方法
|
|
US12410418B2
(en)
|
2019-12-06 |
2025-09-09 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
LT4081305T
(lt)
|
2019-12-24 |
2024-11-25 |
Carna Biosciences, Inc. |
Diacilglicerolio kinazę moduliuojantys junginiai
|
|
US11660307B2
(en)
|
2020-01-27 |
2023-05-30 |
Gilead Sciences, Inc. |
Methods for treating SARS CoV-2 infections
|
|
JP7554841B2
(ja)
|
2020-03-12 |
2024-09-20 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシドを調製する方法
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
US11718637B2
(en)
|
2020-03-20 |
2023-08-08 |
Gilead Sciences, Inc. |
Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
|
|
WO2021207049A1
(en)
|
2020-04-06 |
2021-10-14 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
US12569500B2
(en)
|
2020-05-15 |
2026-03-10 |
Fujian Akeylink Biotechnology Co., Ltd. |
Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV
|
|
CA3179226A1
(en)
|
2020-05-29 |
2021-12-02 |
Tomas Cihlar |
Remdesivir treatment methods
|
|
AU2021296841B2
(en)
|
2020-06-24 |
2025-01-23 |
Gilead Sciences, Inc. |
1'-cyano nucleoside analogs and uses thereof
|
|
PE20230779A1
(es)
|
2020-08-07 |
2023-05-09 |
Gilead Sciences Inc |
Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
|
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
|
AU2021330835B2
(en)
|
2020-08-24 |
2023-12-14 |
Gilead Sciences, Inc. |
Phospholipid compounds and uses thereof
|
|
SI4204421T1
(sl)
|
2020-08-27 |
2024-07-31 |
Gilead Sciences, Inc., |
Spojine in postopki za zdravljenje virusnih okužb
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
EP4337223A1
(en)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
|
|
EP4346772B1
(en)
|
2021-05-26 |
2026-04-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022328698B2
(en)
|
2021-08-18 |
2025-02-20 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
IL315102A
(en)
|
2022-03-02 |
2024-10-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
KR20240154646A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
PE20250419A1
(es)
|
2022-03-03 |
2025-02-14 |
Gilead Sciences Inc |
Compuestos antivirales y metodos de elaboracion y uso de los mismos
|
|
JP2025508941A
(ja)
|
2022-03-03 |
2025-04-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
抗ウイルス化合物並びにその作製及び使用方法
|
|
JP2025519390A
(ja)
|
2022-06-06 |
2025-06-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法
|
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
WO2024173458A1
(en)
|
2023-02-16 |
2024-08-22 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
IL326322A
(en)
|
2023-08-31 |
2026-04-01 |
Gilead Sciences Inc |
Antiviral compounds and methods for their production and use
|
|
US20250090537A1
(en)
|
2023-08-31 |
2025-03-20 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250099476A1
(en)
|
2023-09-06 |
2025-03-27 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20250109157A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|